Fig. 1From: A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myelomaA Swimmer plots demonstrating progress of subjects treated for multiple myeloma with NMP from treatment initiation to discontinuation according to dose level. B Progression-free survival (PFS) of study participants from treatment initiationBack to article page